Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.50 |
| ▸ | HTR1A | P08908 | 6/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6367939 | 0.92 | HTR2C (0.41) | HTR2CSLC6A2SLC6A4TDP1ALDH1A1 | |
| SCHEMBL28092503 | 0.90 | TDP1 (0.46) | HTR2CMAPTTDP1ALDH1A1MAPK1 | |
| SCHEMBL8748376 | 0.81 | HTR2C (0.51) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2233411 | 0.79 | HTR2C (0.63) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5584542 | 0.76 | HTR2C (0.73) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27812820 | 0.76 | HTR2C (0.58) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3536567 | 0.76 | HTR2C (0.50) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5020033 | 0.75 | HTR1A (0.67) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19703133 | 0.75 | HTR2C (0.57) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL358770 | 0.75 | TDP1 (0.61) | MAPTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101827848-B | 2- [ (2- { phenylamino } -1H-pyrrolo [2,3-d ] pyrimidin-4-yl) amino ] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC | 2012-11-07 | — | — | CN | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| CN-101827848-A | 2- [ (2- { phenylamino } -1H-pyrrolo [2,3-d ] pyrimidin-4-yl) amino ] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | SMITHKLINE BEECHAM CORP | 2010-09-08 | — | — | CN | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | HTR2C 1445/4885HTR1A 1439/4885SLC6A2 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.